Analytical Data
-
Gene name
IL-1RA
- Application
-
Alternative Names
IL1RN; IL1-RA; ICIL1RA; IL1ra3; IL1F3; IRAP;IL-1RA; Interleukin-1 Family Member 3; IL1 inhibitor; Anakinra
-
Species
Dog
-
Source
E. coli
-
Tag
N-His
-
Purity
> 97% as determined by SDS-PAGE.
-
Uniprot
Q9BEH0
-
Expression Region
Arg26~Glu176
-
Molecular Weight
24kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-1 receptor antagonist (IL-1RA) is a key regulatory protein in the interleukin-1 cytokine family, playing a crucial role in modulating inflammatory responses. IL-1 is known to contribute significantly to various pathological conditions, including autoimmune diseases, chronic inflammatory disorders, and even certain cancers. The delineation of its role has spurred interest in IL-1RA as a potential therapeutic agent. Recombinant IL-1RA, produced through recombinant DNA technology, has been extensively studied for its ability to antagonize the effects of IL-1 by binding to its receptors without eliciting a biological response. This mechanism makes IL-1RA a promising candidate for treating conditions characterized by excessive IL-1 activity. Clinical trials have demonstrated its efficacy in conditions such as rheumatoid arthritis and other inflammatory diseases. Moreover, ongoing research is exploring its potential application in a broader range of inflammatory and degenerative diseases, highlighting IL-1RA's significance in therapeutic strategies aimed at restoring immune homeostasis and mitigating disease progression. The exploration of IL-1RA as a treatment provides hope for patients suffering from debilitating conditions driven by chronic inflammation.
